Joel Habener, endocrinlogo, y su equipo identificaron la forma bioactiva del receptor del pptido 1 similar al glucagn y de manera simultnea con otros investigadores, como Jens Holst, Daniel Drucker y Svetlana Mostov, demostraron su capacidad para estimular la secrecin de insulina dependiente de glucosa, inhibir el glucagn y enviar seales al cerebro relacionadas con saciedad
Therapeutic Goods Administration (TGA)
But without formal safety studies, we don't know about long-term risks
Let us look at the side effects of GLP-1 agonists: Loss of appetite Nausea Vomiting Diarrhoea Dizziness Mild tachycardia (fast heartbeat)
Every day we dont solve for the cost and coverage of these drugs, we risk the greatest acceleration of health inequity of our lifetimecreating an even greater gap in health equity that I believe will have a profound and durable impact on our society that will be increasingly difficult to reverse